Celldex Therapeutics reports third quarter net loss of $67.0 million on revenue of $0.0 million

Reuters11-11
Celldex <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter net loss of $67.0 million on revenue of $0.0 million

Celldex Therapeutics Inc. reported a net loss of $67.0 million, or ($1.01) per share, for the third quarter of 2025, compared to a net loss of $42.1 million, or ($0.64) per share, for the same period in 2024. For the nine months ended September 30, 2025, net loss was $177.4 million, or ($2.67) per share, versus $110.8 million, or ($1.74) per share, for the corresponding period in 2024. Total revenue was $0.0 million in the third quarter of 2025 and $1.4 million for the nine-month period, compared to $3.2 million and $5.8 million, respectively, in 2024, primarily due to a decrease in services performed under agreements with Rockefeller University. Cash, cash equivalents and marketable securities totaled $583.2 million as of September 30, 2025. The company highlighted positive Phase 2 results for barzolvolimab in chronic spontaneous urticaria, cold urticaria, and symptomatic dermographism, as well as positive Phase 1 data for CDX-622. Celldex expects its cash position to fund planned operations through 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celldex Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9572570-en) on November 10, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment